A Detailed Analysis of the CRBSI Treatment Market Based on the Continuous Innovation in Antimicrobial Therapies
Report ID: PMRREP33952
Number of Pages: 223
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: January-2024
1. Executive Summary
1.1. Global CRBSI Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Class Lifecycle Analysis
2.4. Global CRBSI Treatment Market: Value Chain
2.4.1. List of Route of Administration Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Route of Administration Landscape
3. Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global CRBSI Treatment Market Outlook: Drug Class
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
3.3.3.1. Cloxacillin
3.3.3.2. Ceftazidime
3.3.3.3. Cefazoline
3.3.3.4. Daptomycin
3.3.3.5. Vancomycin
3.3.3.6. Teicoplanin
3.3.3.7. Echinocandin
3.3.3.8. Others
3.4. Market Attractiveness Analysis: Drug Class
3.5. Global CRBSI Treatment Market Outlook: Route of Administration
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
3.5.3.1. Oral
3.5.3.2. Injectable
3.6. Market Attractiveness Analysis: Route of Administration
3.7. Global CRBSI Treatment Market Outlook: Indication
3.7.1. Introduction / Key Findings
3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication, 2018 - 2022
3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
3.7.3.1. Bacterial Infections
3.7.3.2. Fungal Infection
3.7.3.3. Viral and Parasitic Infections
3.8. Market Attractiveness Analysis: Indication
3.9. Global CRBSI Treatment Market Outlook: Distribution Channel
3.9.1. Introduction / Key Findings
3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.9.3.1. Hospital Pharmacies
3.9.3.2. Retail Pharmacies
3.9.3.3. Drug Store
3.9.3.4. Online Pharmacies
3.10. Market Attractiveness Analysis: Distribution Channel
4. Global CRBSI Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug Class
5.3.3. By Route of Administration
5.3.4. By Indication
5.3.5. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
5.5.1. Cloxacillin
5.5.2. Ceftazidime
5.5.3. Cefazoline
5.5.4. Daptomycin
5.5.5. Vancomycin
5.5.6. Teicoplanin
5.5.7. Echinocandin
5.5.8. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
5.6.1. Oral
5.6.2. Injectable
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
5.7.1. Bacterial Infections
5.7.2. Fungal Infection
5.7.3. Viral and Parasitic Infections
5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.8.1. Hospital Pharmacies
5.8.2. Retail Pharmacies
5.8.3. Drug Store
5.8.4. Online Pharmacies
5.9. Market Attractiveness Analysis
6. Europe Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug Class
6.3.3. By Route of Administration
6.3.4. By Indication
6.3.5. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
6.5.1. Cloxacillin
6.5.2. Ceftazidime
6.5.3. Cefazoline
6.5.4. Daptomycin
6.5.5. Vancomycin
6.5.6. Teicoplanin
6.5.7. Echinocandin
6.5.8. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
6.6.1. Oral
6.6.2. Injectable
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
6.7.1. Bacterial Infections
6.7.2. Fungal Infection
6.7.3. Viral and Parasitic Infections
6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.8.1. Hospital Pharmacies
6.8.2. Retail Pharmacies
6.8.3. Drug Store
6.8.4. Online Pharmacies
6.9. Market Attractiveness Analysis
7. East Asia Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug Class
7.3.3. By Route of Administration
7.3.4. By Indication
7.3.5. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
7.5.1. Cloxacillin
7.5.2. Ceftazidime
7.5.3. Cefazoline
7.5.4. Daptomycin
7.5.5. Vancomycin
7.5.6. Teicoplanin
7.5.7. Echinocandin
7.5.8. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
7.6.1. Oral
7.6.2. Injectable
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
7.7.1. Bacterial Infections
7.7.2. Fungal Infection
7.7.3. Viral and Parasitic Infections
7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.8.1. Hospital Pharmacies
7.8.2. Retail Pharmacies
7.8.3. Drug Store
7.8.4. Online Pharmacies
7.9. Market Attractiveness Analysis
8. South Asia & Oceania Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Route of Administration
8.3.4. By Indication
8.3.5. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
8.5.1. Cloxacillin
8.5.2. Ceftazidime
8.5.3. Cefazoline
8.5.4. Daptomycin
8.5.5. Vancomycin
8.5.6. Teicoplanin
8.5.7. Echinocandin
8.5.8. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
8.6.1. Oral
8.6.2. Injectable
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
8.7.1. Bacterial Infections
8.7.2. Fungal Infection
8.7.3. Viral and Parasitic Infections
8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.8.1. Hospital Pharmacies
8.8.2. Retail Pharmacies
8.8.3. Drug Store
8.8.4. Online Pharmacies
8.9. Market Attractiveness Analysis
9. Latin America Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Indication
9.3.5. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
9.5.1. Cloxacillin
9.5.2. Ceftazidime
9.5.3. Cefazoline
9.5.4. Daptomycin
9.5.5. Vancomycin
9.5.6. Teicoplanin
9.5.7. Echinocandin
9.5.8. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
9.6.1. Oral
9.6.2. Injectable
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
9.7.1. Bacterial Infections
9.7.2. Fungal Infection
9.7.3. Viral and Parasitic Infections
9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.8.1. Hospital Pharmacies
9.8.2. Retail Pharmacies
9.8.3. Drug Store
9.8.4. Online Pharmacies
9.9. Market Attractiveness Analysis
10. Middle East & Africa Global CRBSI Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Indication
10.3.5. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
10.5.1. Cloxacillin
10.5.2. Ceftazidime
10.5.3. Cefazoline
10.5.4. Daptomycin
10.5.5. Vancomycin
10.5.6. Teicoplanin
10.5.7. Echinocandin
10.5.8. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
10.6.1. Oral
10.6.2. Injectable
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
10.7.1. Bacterial Infections
10.7.2. Fungal Infection
10.7.3. Viral and Parasitic Infections
10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Drug Store
10.8.4. Online Pharmacies
10.9. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Drug Class Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Aurobindo Pharma Limited
11.3.1.1. Overview
11.3.1.2. Segments and Drug Class
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. B. Braun Medical Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Drug Class
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Eli Lilly and Company
11.3.3.1. Overview
11.3.3.2. Segments and Drug Class
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Fresenius SE & Co. KGaA
11.3.4.1. Overview
11.3.4.2. Segments and Drug Class
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. GSK plc
11.3.5.1. Overview
11.3.5.2. Segments and Drug Class
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Merck & Co., Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Drug Class
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Mylan N.V. (Viatris)
11.3.7.1. Overview
11.3.7.2. Segments and Drug Class
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Novartis
11.3.8.1. Overview
11.3.8.2. Segments and Drug Class
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Pfizer Inc.
11.3.9.1. Overview
11.3.9.2. Segments and Drug Class
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Sanofi AG
11.3.10.1. Overview
11.3.10.2. Segments and Drug Class
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. SteriMax Inc.
11.3.11.1. Overview
11.3.11.2. Segments and Drug Class
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Teva Pharmaceutical Industries Ltd.
11.3.12.1. Overview
11.3.12.2. Segments and Drug Class
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
